Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 2862173, 13 pages
http://dx.doi.org/10.1155/2016/2862173
Review Article

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background

1Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA
2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada T6G 2H7
3Department of General Surgery, Tongji Hospital, Huazhong Science & Technology University, Wuhan, Hubei 430030, China
4Department of Medicine, University of Louisville, Louisville, KY 40208, USA
5Department of Nutrition and Food Science, Texas A&M University, Houston, TX 77843, USA

Received 26 January 2016; Accepted 14 April 2016

Academic Editor: Greger Lindberg

Copyright © 2016 Jinsheng Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Demir, S. Lang, and H. Steffen, “Nonalcoholic fatty liver disease: current status and future directions,” Journal of Digestive Diseases, vol. 16, no. 10, pp. 541–557, 2015. View at Publisher · View at Google Scholar
  2. D. G. Tiniakos, M. B. Vos, and E. M. Brunt, “Nonalcoholic fatty liver disease: pathology and pathogenesis,” Annual Review of Pathology: Mechanisms of Disease, vol. 5, pp. 145–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Abu-Shanab and E. M. M. Quigley, “The role of the gut microbiota in nonalcoholic fatty liver disease,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 12, pp. 691–701, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Angulo, “Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?” Hepatology, vol. 51, no. 2, pp. 373–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Soderberg, P. Stål, J. Askling et al., “Decreased survival of subjects with elevated liver function tests during a 28-year follow-up,” Hepatology, vol. 51, no. 2, pp. 595–602, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Zhou, G. Llauradó, M. Orešič, T. Hyötyläinen, M. Orho-Melander, and H. Yki-Järvinen, “Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2,” Journal of Hepatology, vol. 62, no. 3, pp. 657–663, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Lomonaco, C. Ortiz-Lopez, B. Orsak et al., “Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease,” Hepatology, vol. 55, no. 5, pp. 1389–1397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Pagano, G. Pacini, G. Musso et al., “Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association,” Hepatology, vol. 35, no. 2, pp. 367–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., “Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities,” Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-E. Dumas, J. Kinross, and J. K. Nicholson, “Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease,” Gastroenterology, vol. 146, no. 1, pp. 46–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Schuppan and J. M. Schattenberg, “Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches,” Journal of Gastroenterology and Hepatology, vol. 28, supplement 1, pp. 68–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two ‘hits’?” Gastroenterology, vol. 114, no. 4 I, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Berson, V. De Beco, P. Letteron et al., “Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes,” Gastroenterology, vol. 114, no. 4, pp. 764–774, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Johnson, J. J. Milner, and L. Makowski, “The inflammation highway: metabolism accelerates inflammatory traffic in obesity,” Immunological Reviews, vol. 249, no. 1, pp. 218–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. C. Matherly and P. Puri, “Mechanisms of simple hepatic steatosis: not so simple after all,” Clinics in Liver Disease, vol. 16, no. 3, pp. 505–524, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Barbuio, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Velloso, “Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet,” Journal of Endocrinology, vol. 194, no. 3, pp. 539–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Tilg, “The role of cytokines in non-alcoholic fatty liver disease,” Digestive Diseases, vol. 28, no. 1, pp. 179–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Hasenour, E. D. Berglund, and D. H. Wasserman, “Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver,” Molecular and Cellular Endocrinology, vol. 366, no. 2, pp. 152–162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Ouyang, P. Cirillo, Y. Sautin et al., “Fructose consumption as a risk factor for non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 48, no. 6, pp. 993–999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Assy, G. Nasser, I. Kamayse et al., “Soft drink consumption linked with fatty liver in the absence of traditional risk factors,” Canadian Journal of Gastroenterology, vol. 22, no. 10, pp. 811–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Zelber-Sagi, D. Nitzan-Kaluski, R. Goldsmith et al., “Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study,” Journal of Hepatology, vol. 47, no. 5, pp. 711–717, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. V. Machado, P. Ravasco, L. Jesus et al., “Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet,” Scandinavian Journal of Gastroenterology, vol. 43, no. 1, pp. 95–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. Lambert, M. A. Ramos-Roman, J. D. Browning, and E. J. Parks, “Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease,” Gastroenterology, vol. 146, no. 3, pp. 726–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. L. C. Hudgins, T. S. Parker, D. M. Levine, and M. K. Hellerstein, “A dual sugar challenge test for lipogenic sensitivity to dietary fructose,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 861–868, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Lecoultre, L. Egli, G. Carrel et al., “Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans,” Obesity, vol. 21, no. 4, pp. 782–785, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. E. J. Parks, L. E. Skokan, M. T. Timlin, and C. S. Dingfelder, “Dietary sugars stimulate fatty acid synthesis in adults,” Journal of Nutrition, vol. 138, no. 6, pp. 1039–1046, 2008. View at Google Scholar · View at Scopus
  28. K. L. Stanhope, J. M. Schwarz, N. L. Keim et al., “Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans,” The Journal of Clinical Investigation, vol. 119, no. 5, pp. 1322–1334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. F. Abdelmalek, A. Suzuki, C. Guy et al., “Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 6, pp. 1961–1971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Lin, R. Yang, P. T. Tarr et al., “Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP,” Cell, vol. 120, no. 2, pp. 261–273, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Mancina, N. Matikainen, C. Maglio et al., “Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 5, pp. E821–E825, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Tilg and A. R. Moschen, “Inflammatory mechanisms in the regulation of insulin resistance,” Molecular Medicine, vol. 14, no. 3-4, pp. 222–231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Gastaldelli, K. Cusi, M. Pettiti et al., “Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects,” Gastroenterology, vol. 133, no. 2, pp. 496–506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Sevastianova, A. Kotronen, A. Gastaldelli et al., “Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss—induced decrease in liver fat in humans,” The American Journal of Clinical Nutrition, vol. 94, no. 1, pp. 104–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Kantartzis, A. Peter, F. Machicao et al., “Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene,” Diabetes, vol. 58, no. 11, pp. 2616–2623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Kozlitina, E. Smagris, S. Stender et al., “Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease,” Nature Genetics, vol. 46, no. 4, pp. 352–356, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Kantartzis, F. Machicao, J. Machann et al., “The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans,” Clinical Science, vol. 116, no. 6, pp. 531–537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. M. E. Visser, N. M. Lammers, A. J. Nederveen et al., “Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia,” Diabetologia, vol. 54, no. 8, pp. 2113–2121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Amaro, E. Fabbrini, M. Kars et al., “Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia,” Gastroenterology, vol. 139, no. 1, pp. 149–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. N. A. Palmer, C. Maglio, C. Pirazzi et al., “Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant,” PLoS ONE, vol. 7, no. 6, Article ID e39362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Gaggini, M. Morelli, E. Buzzigoli, R. A. DeFronzo, E. Bugianesi, and A. Gastaldelli, “Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease,” Nutrients, vol. 5, no. 5, pp. 1544–1560, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Fuchs and A. J. Sanyal, “Lipotoxicity in NASH,” Journal of Hepatology, vol. 56, no. 1, pp. 291–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Simonen, A. Kotronen, M. Hallikainen et al., “Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity,” Journal of Hepatology, vol. 54, no. 1, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Arguello, E. Balboa, M. Arrese, and S. Zanlungo, “Recent insights on the role of cholesterol in non-alcoholic fatty liver disease,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1852, no. 9, pp. 1765–1778, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Malhi, S. F. Bronk, N. W. Werneburg, and G. J. Gores, “Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis,” The Journal of Biological Chemistry, vol. 281, no. 17, pp. 12093–12101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Sharifnia, J. Antoun, T. G. C. Verriere et al., “Hepatic TLR4 signaling in obese NAFLD,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 309, no. 4, pp. G270–G278, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Serviddio, F. Bellanti, R. Tamborra et al., “Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model,” European Journal of Clinical Investigation, vol. 38, no. 4, pp. 245–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Jiang, M. Zhao, and W. An, “Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance,” Journal of Molecular Medicine, vol. 89, no. 12, pp. 1207–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. X. Jin, Y.-D. Yang, K. Chen et al., “HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD,” Journal of Hepatology, vol. 50, no. 5, pp. 1019–1028, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. P. Day, “Pathogenesis of steatohepatitis,” Best Practice & Research Clinical Gastroenterology, vol. 16, no. 5, pp. 663–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. H. A. Sadek, P. A. Szweda, and L. I. Szweda, “Modulation of mitochondrial complex I activity by reversible Ca2+ and NADH mediated superoxide anion dependent inhibition,” Biochemistry, vol. 43, no. 26, pp. 8494–8502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. C. C. Kujoth, A. Hiona, T. D. Pugh et al., “Medicine: mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging,” Science, vol. 309, no. 5733, pp. 481–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. C. P. Day, “Non-alcoholic fatty liver disease: current concepts and management strategies,” Clinical Medicine, vol. 6, no. 1, pp. 19–25, 2006. View at Google Scholar · View at Scopus
  54. G. H. Koek, P. R. Liedorp, and A. Bast, “The role of oxidative stress in non-alcoholic steatohepatitis,” Clinica Chimica Acta, vol. 412, no. 15-16, pp. 1297–1305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Nowicka and J. Kruk, “Occurrence, biosynthesis and function of isoprenoid quinones,” Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1797, no. 9, pp. 1587–1605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Pessayre, “Role of mitochondria in non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 22, supplement 1, pp. S20–S27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Novo, C. Busletta, L. V. D. Bonzo et al., “Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells,” Journal of Hepatology, vol. 54, no. 5, pp. 964–974, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. G. S. Hotamisligil, “Endoplasmic reticulum stress and the inflammatory basis of metabolic disease,” Cell, vol. 140, no. 6, pp. 900–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. U. Özcan, Q. Cao, E. Yilmaz et al., “Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes,” Science, vol. 306, no. 5695, pp. 457–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Lee and U. Ozcan, “Unfolded protein response signaling and metabolic diseases,” The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1203–1211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Hetz, “The unfolded protein response: controlling cell fate decisions under ER stress and beyond,” Nature Reviews Molecular Cell Biology, vol. 13, no. 2, pp. 89–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Zambo, L. Simon-Szabo, P. Szelenyi et al., “Lipotoxicity in the liver,” World Journal of Hepatology, vol. 5, no. 10, pp. 550–557, 2013. View at Google Scholar
  64. P. S. Langendijk, F. Schut, G. J. Jansen et al., “Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples,” Applied and Environmental Microbiology, vol. 61, no. 8, pp. 3069–3075, 1995. View at Google Scholar · View at Scopus
  65. G. Musso, M. Cassader, S. Cohney et al., “Emerging liver-kidney interactions in nonalcoholic fatty liver disease,” Trends in Molecular Medicine, vol. 21, no. 10, pp. 645–662, 2015. View at Publisher · View at Google Scholar
  66. I. A. Kirpich, L. S. Marsano, and C. J. McClain, “Gut-liver axis, nutrition, and non-alcoholic fatty liver disease,” Clinical Biochemistry, vol. 48, no. 13-14, pp. 923–930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Lin, J. Lu, Y. Wang et al., “Naturally occurring stilbenoid TSG reverses non-alcoholic fatty liver diseases via gut-liver axis,” PLoS ONE, vol. 10, no. 10, Article ID e0140346, 2015. View at Publisher · View at Google Scholar
  68. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027–1031, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Schwiertz, D. Taras, K. Schäfer et al., “Microbiota and SCFA in lean and overweight healthy subjects,” Obesity, vol. 18, no. 1, pp. 190–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. R. E. Ley, F. Bäckhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight, and J. I. Gordon, “Obesity alters gut microbial ecology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 31, pp. 11070–11075, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Microbial ecology: human gut microbes associated with obesity,” Nature, vol. 444, no. 7122, pp. 1022–1023, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D.-J. Reijngoud, and B. M. Bakker, “The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism,” Journal of Lipid Research, vol. 54, no. 9, pp. 2325–2340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. G. den Besten, A. Bleeker, A. Gerding et al., “Short-chain fatty acids protect against high-fat diet–induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation,” Diabetes, vol. 64, no. 7, pp. 2398–2408, 2015. View at Publisher · View at Google Scholar
  74. A. L. Buchman, M. D. Dubin, A. A. Moukarzel et al., “Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation,” Hepatology, vol. 22, no. 5, pp. 1399–1403, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. M.-E. Dumas, R. H. Barton, A. Toye et al., “Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12511–12516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. M. D. Spencer, T. J. Hamp, R. W. Reid, L. M. Fischer, S. H. Zeisel, and A. A. Fodor, “Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency,” Gastroenterology, vol. 140, no. 3, pp. 976–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. D. W. Russell, “The enzymes, regulation, and genetics of bile acid synthesis,” Annual Review of Biochemistry, vol. 72, pp. 137–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. J. M. Ridlon, D.-J. Kang, and P. B. Hylemon, “Bile salt biotransformations by human intestinal bacteria,” Journal of Lipid Research, vol. 47, no. 2, pp. 241–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. S. I. Sayin, A. Wahlström, J. Felin et al., “Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist,” Cell Metabolism, vol. 17, no. 2, pp. 225–235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. F. G. Schaap, M. Trauner, and P. L. M. Jansen, “Bile acid receptors as targets for drug development,” Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 1, pp. 55–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Li, K. Jadhav, and Y. Zhang, “Bile acid receptors in non-alcoholic fatty liver disease,” Biochemical Pharmacology, vol. 86, no. 11, pp. 1517–1524, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. R. H. McMahan, X. X. Wang, L. L. Cheng et al., “Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease,” The Journal of Biological Chemistry, vol. 288, no. 17, pp. 11761–11770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Cope, T. Risby, and A. M. Diehl, “Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis,” Gastroenterology, vol. 119, no. 5, pp. 1340–1347, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Nair, K. Cope, R. H. Terence, and A. M. Diehl, “Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 96, no. 4, pp. 1200–1204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Zhu, S. S. Baker, C. Gill et al., “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH,” Hepatology, vol. 57, no. 2, pp. 601–609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. S. Baker, R. D. Baker, W. Liu, N. J. Nowak, and L. Zhu, “Role of alcohol metabolism in non-alcoholic steatohepatitis,” PLoS ONE, vol. 5, no. 3, Article ID e9570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. J. Engstler, T. Aumiller, C. Degen et al., “Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease,” Gut, 2015. View at Publisher · View at Google Scholar
  89. I. C. de Medeiros and J. G. de Lima, “Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease?—a mechanistic hypothesis,” Medical Hypotheses, vol. 85, no. 2, pp. 148–152, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Artis, “Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut,” Nature Reviews Immunology, vol. 8, no. 6, pp. 411–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Q. Yang, H. Z. Lin, M. D. Lane, M. Clemens, and A. M. Diehl, “Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2557–2562, 1997. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Brun, I. Castagliuolo, V. Di Leo et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 292, no. 2, pp. G518–G525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Miele, V. Valenza, G. La Torre et al., “Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease,” Hepatology, vol. 49, no. 6, pp. 1877–1887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. F. Laugerette, C. Vors, A. Géloën et al., “Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation,” Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 53–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Yuan, S. S. Baker, W. Liu et al., “Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis,” Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1292–1298, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Medzhitov, “Toll-like receptors and innate immunity,” Nature Reviews Immunology, vol. 1, no. 2, pp. 135–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. D. M. L. Tsukumo, M. A. Carvalho-Filho, J. B. C. Carvalheira et al., “Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance,” Diabetes, vol. 56, no. 8, pp. 1986–1998, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Miura, Y. Kodama, S. Inokuchi et al., “Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice,” Gastroenterology, vol. 139, no. 1, pp. 323–334.e7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Vijay-Kumar, J. D. Aitken, F. A. Carvalho et al., “Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5,” Science, vol. 328, no. 5975, pp. 228–231, 2010. View at Publisher · View at Google Scholar
  100. M. Wlodarska, C. A. Thaiss, R. Nowarski et al., “NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion,” Cell, vol. 156, no. 5, pp. 1045–1059, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Henao-Mejia, E. Elinav, C. Jin et al., “Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity,” Nature, vol. 482, no. 7384, pp. 179–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. A. K. Leamy, R. A. Egnatchik, and J. D. Young, “Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease,” Progress in Lipid Research, vol. 52, no. 1, pp. 165–174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. N. de Wit, M. Derrien, H. Bosch-Vermeulen et al., “Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 303, no. 5, pp. G589–G599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. J. J. Ronis, S. Korourian, M. Zipperman, R. Hakkak, and T. M. Badger, “Dietary saturated fat reduces alcoholic hepatotoxicity in rats by altering fatty acid metabolism and membrane composition,” Journal of Nutrition, vol. 134, no. 4, pp. 904–912, 2004. View at Google Scholar · View at Scopus
  105. A. A. Nanji, K. Jokelainen, G. L. Tipoe, A. Rahemtulla, and A. J. Dannenberg, “Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration,” Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 2, pp. 638–644, 2001. View at Google Scholar · View at Scopus
  106. I. A. Kirpich, W. Feng, Y. Wang et al., “The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease,” Alcoholism: Clinical and Experimental Research, vol. 36, no. 5, pp. 835–846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Wei, D. Wang, F. Topczewski, and M. J. Pagliassotti, “Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 2, pp. E275–E281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Wang, Y. Wei, and M. J. Pagliassotti, “Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis,” Endocrinology, vol. 147, no. 2, pp. 943–951, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. G. Solinas, W. Naugler, F. Galimi, M.-S. Lee, and M. Karin, “Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16454–16459, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Chen, M. Torralba, J. Tan et al., “Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice,” Gastroenterology, vol. 148, no. 1, pp. 203–214.e16, 2015. View at Publisher · View at Google Scholar · View at Scopus
  111. J. B. Moore, P. J. Gunn, and B. A. Fielding, “The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease,” Nutrients, vol. 6, no. 12, pp. 5679–5703, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. T. A. O'Sullivan, W. H. Oddy, A. P. Bremner et al., “Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity,” Journal of Pediatric Gastroenterology and Nutrition, vol. 58, no. 5, pp. 624–631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. D. R. Mager, C. Patterson, S. So, C. D. Rogenstein, L. J. Wykes, and E. A. Roberts, “Dietary and physical activity patterns in children with fatty liver,” European Journal of Clinical Nutrition, vol. 64, no. 6, pp. 628–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. P. Jegatheesan, S. Beutheu, G. Ventura et al., “Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease,” Clinical Nutrition, vol. 35, no. 1, pp. 175–182, 2016. View at Publisher · View at Google Scholar
  115. R. Jin, A. Willment, S. S. Patel et al., “Fructose induced endotoxemia in pediatric nonalcoholic fatty liver disease,” International Journal of Hepatology, vol. 2014, Article ID 560620, 8 pages, 2014. View at Publisher · View at Google Scholar
  116. Y. Ritze, G. Bárdos, A. Claus et al., “Lactobacillus rhamnosus GG Protects against non-alcoholic fatty liver disease in mice,” PLoS ONE, vol. 9, no. 1, Article ID e80169, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Wagnerberger, A. Spruss, G. Kanuri et al., “Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model,” Journal of Nutritional Biochemistry, vol. 24, no. 3, pp. 531–538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. F.-C. Hsieh, C.-L. Lee, C.-Y. Chai, W.-T. Chen, Y.-C. Lu, and C.-S. Wu, “Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats,” Nutrition and Metabolism, vol. 10, no. 1, article 35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Wagnerberger, A. Spruss, G. Kanuri et al., “Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis,” British Journal of Nutrition, vol. 107, no. 12, pp. 1727–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. F. S. Macaluso, M. Maida, and S. Petta, “Genetic background in nonalcoholic fatty liver disease: a comprehensive review,” World Journal of Gastroenterology, vol. 21, no. 39, pp. 11088–11111, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. R. M. Mancina, P. Dongiovanni, S. Petta et al., “The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent,” Gastroenterology, vol. 150, no. 5, pp. 1219–1230, 2016. View at Publisher · View at Google Scholar
  122. Q. M. Anstee and C. P. Day, “The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2,” Seminars in Liver Disease, vol. 35, no. 3, pp. 270–290, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. P. Pingitore, C. Pirazzi, R. M. Mancina et al., “Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1841, no. 4, pp. 574–580, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. S. He, C. McPhaul, J. Z. Li et al., “A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6706–6715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Mondul, R. M. Mancina, A. Merlo et al., “PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity,” Journal of Nutrition, vol. 145, no. 8, pp. 1687–1691, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Kovarova, I. Konigsrainer, A. Konigsrainer et al., “The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 12, pp. E1568–E1574, 2015. View at Publisher · View at Google Scholar
  127. C. Pirazzi, L. Valenti, B. M. Motta et al., “PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells,” Human Molecular Genetics, vol. 23, no. 15, pp. 4077–4085, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Romeo, J. Kozlitina, C. Xing et al., “Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease,” Nature Genetics, vol. 40, no. 12, pp. 1461–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Sookoian and C. J. Pirola, “Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease,” Hepatology, vol. 53, no. 6, pp. 1883–1894, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. Q. M. Anstee and C. P. Day, “The genetics of NAFLD,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 11, pp. 645–655, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Li, C. Xing, Z. Tian, and H.-C. Ku, “Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population,” BMC Medical Genetics, vol. 13, article 113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. S. S. Lee, Y.-S. Byoun, S.-H. Jeong et al., “Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in korea,” Digestive Diseases and Sciences, vol. 59, no. 12, pp. 2967–2974, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Kawaguchi, Y. Sumida, A. Umemura et al., “Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese,” PLoS ONE, vol. 7, no. 6, Article ID e38322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Petta, E. Vanni, E. Bugianesi et al., “PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 41, no. 10, pp. 939–948, 2015. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Viganò, L. Valenti, P. Lampertico et al., “Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B,” Hepatology, vol. 58, no. 4, pp. 1245–1252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. E. Trepo, E. Guyot, N. Ganne-Carrie et al., “PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis,” Hepatology, vol. 55, no. 4, pp. 1307–1308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. Y.-L. Liu, G. L. Patman, J. B. S. Leathart et al., “Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma,” Journal of Hepatology, vol. 61, no. 1, pp. 75–81, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. M. A. Burza, C. Pirazzi, C. Maglio et al., “PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals,” Digestive and Liver Disease, vol. 44, no. 12, pp. 1037–1041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Krawczyk, C. S. Stokes, S. Romeo, and F. Lammert, “HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance,” Journal of Hepatology, vol. 62, no. 4, pp. 980–981, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Krawczyk, P. Portincasa, and F. Lammert, “PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease,” Seminars in Liver Disease, vol. 33, no. 4, pp. 369–379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. Y.-L. Liu, H. L. Reeves, A. D. Burt et al., “TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease,” Nature Communications, vol. 5, article 4309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. P. Dongiovanni, S. Petta, C. Maglio et al., “Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease,” Hepatology, vol. 61, no. 2, pp. 506–514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  143. G. Musso, M. Cassader, E. Paschetta, and R. Gambino, “TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD,” Journal of Hepatology, vol. 64, no. 4, pp. 979–981, 2016. View at Publisher · View at Google Scholar
  144. T. Le Roy, M. Llopis, P. Lepage et al., “Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice,” Gut, vol. 62, no. 12, pp. 1787–1794, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Ussar, N. W. Griffin, O. Bezy et al., “Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome,” Cell Metabolism, vol. 22, no. 3, pp. 516–530, 2015. View at Publisher · View at Google Scholar